AstraZeneca news. Headlines for AZN.

AstraZeneca News

Prices

Results Calendar charts

Charts

Watchlist

Share Tips

Here are all todays headlines related to AstraZeneca News. If you wish to drill deeper to view past AstraZeneca News items, follow the next 20 headlines link at the foot of the page.

AstraZeneca expects later cancer trial completion

12-03-2018

AstraZeneca has pushed back the expected completion of the Phase III 'Mystic' clinical trial of its Imfinzi immunotherapy treatment of metastatic non-small cell lung cancer.

Astra and MSD get positive cancer news from EU agency

23-02-2018

AstraZeneca and US partner Merck & Co (MSD) have received a positive opinion from European drug regulators over their ovarian, fallopian tube, or peritoneal cancer therapy.

Monday broker round-up

19-02-2018

Softcat plc: Berenberg upgrades to buy with a target price of 650p.

AstraZeneca's Imfinzi clears another FDA hurdle

19-02-2018

AstraZeneca and MedImmune, its global biologics research and development arm, announced on Monday that the US Food and Drug Administration has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

AstraZeneca's selumetinib gets FDA designation for new treatment

15-02-2018

AstraZeneca, along with Merck & Co, announced on Thursday that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Thursday broker round-up

08-02-2018

Rangold resources: HSBC upgrades to buy with a target price of 7,700p.

AstraZeneca earnings fall less than expected, faces US lawsuit from Array

02-02-2018

Drug maker AstraZeneca reported total revenue down 2% last year and core earnings per share down just 1%, having a year ago feared a fall in the mid-teens, but news of a US lawsuit rained on the parade somewhat.

Sunday newspaper round-up: Rate hike, Brexit, profit warnings, buybacks, Sky

28-01-2018

Stronger than expected growth numbers have fuelled expectations that another rise in interest rates is on the way, with City traders now seeing a May rise from the Bank of England as an even-money bet. The economy expanded by 0.5% in the final quarter of 2017, according to official figures last week, faster than economists had forecast. - Sunday Times

Friday broker round-up

26-01-2018

Diageo plc: Berenberg retains hold with a target price of 2,550p.

AstraZeneca to press on with triple-dose COPD drug after Kronos success

26-01-2018

AstraZeneca found a statistically significant improvement in eight out of nine lung functions for patients tested with its 'PT010' triple-combination drug delivered with a inhaler in late-stage clinical trials.

Friday broker round-up

19-01-2018

Fever-Tree: Jefferies initiates buy with a target price of 3000p.

AstraZeneca gets approvals for Fasenra and Lynparza in Japan

19-01-2018

AstraZeneca announced the approval of two of its drugs in Japan on Friday - Fasenra (benralizumab) as an add-on treatment for bronchial asthma in patients who continue to experience asthma exacerbations despite treatment with high-dose inhaled corticosteroid and other asthma controllers, and Lynparza (olaparib) tablets at 300mg twice daily, for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.

AstraZeneca secures European approval for asthma drug

10-01-2018

Biopharmaceutical company AstraZeneca has received approval from the European Commission (EC) for its asthma medicine Fasenra.

Tuesday broker round-up

09-01-2018

Mothercare: JP Morgan downgrades to underweight with a target price of 40p.

Next 20 headlines >>

Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk

Get a free widget for your website with our latest headlines.

You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.

Visit our widget builder